SALEM, Mass., Nov. 19 /PRNewswire/ -- LaVoie Group, a life sciences focused, corporate, investor and public relations firm, today announced that it has been selected as agency of record by Agile Therapeutics, of Princeton, NJ, and The GI Company, of Framingham, MA.

    Donna LaVoie, President and CEO, commented, "LaVoie Group is engaged in providing strategic communications counsel and tactical execution to these exciting companies as they accelerate interactions with the venture capital, biopharmaceutical and professional medical communities. The addition of these clients underscores the increasingly diverse nature of our life sciences roster."

    Ms. LaVoie continued, "Agile Therapeutics is a specialty pharmaceutical company addressing unmet needs in women''s healthcare, while The GI Company specializes in developing drugs for gastrointestinal and related diseases. Both are poised to make an impact in their respective therapeutic areas."

    About Agile Therapeutics

    Agile Therapeutics is a specialty pharmaceutical company focused on the development of innovative women''s healthcare products. The company''s late- stage products are driven by a market need for a convenient and reliable low- dose contraceptive patch. Agile is capitalizing on its executive team''s proven expertise in transdermal technology, drug development, and fertility management to build a pipeline of women''s health products through line extensions and/or in-licensing. For more information, visit www.agiletherapeutics.com.

    About The GI Company

    The GI Company is a clinical-stage biotechnology company highly specialized at developing drugs to treat gastrointestinal and related diseases. The company''s lead clinical candidate, Intestinal Trefoil Factor (ITF), is being developed for the treatment of oral mucositis, a common, debilitating complication resulting from high-dose chemotherapy and/or radiotherapy. Phase II clinical results are expected to be released in the 1st half of 2008. The GI Company also has pre-clinical development programs in enteritis/proctitis, inflammatory bowel disease, erosive gastroesophageal reflux disease, peptic ulcer disease and gastrointestinal motility disorders, as well as clinical programs in erosive gastritis (NSAID induced), ulcerative colitis and corneal wound healing. For more information, visit www.thegicompany.com.

    About LaVoie Group

    LaVoie Group provides senior level strategic counsel and tactical implementation of public, investor and corporate communications programs designed to properly position, create visibility and drive value for each client. Our clients range from private start-ups to industry leaders in life sciences. For more information, visit www.lavoiegroup.com.

    Source: LaVoie Group